@entity14855 inhibition with @entity1140 has been used after renal transplantation (RTPL) as rescue therapy for insufficient immunological control or if @entity205 (CSA) @entity137 occurred. Neurologic side-effects occur but are rare in @entity1 , usually presenting as @entity400 ; however, serious complications, e.g. the @entity16757 are also documented. Twenty @entity1 (10 @entity1 ) were switched to @entity1140 : 11 (55%) for immunological reasons (n = 9: @entity134 -resistant rejection; n = 2: recurrent rejections) and nine for CSA side-effects. @entity1140 was started at a median of 8 wk (range 10 d to 8.7 yr) after RTPL and was continued for a median of 2.5 yr (range 5 wk to 4.6 yr). Renal function significantly improved over a period of 12 months following conversion to @entity1140 (glomerular filtration rate 56 +/- 19 vs. 66 +/- 16 mL/ @entity1009 .73 m2; p < 0.03; n = 13). Fifteen of 20 (75%) @entity1 tolerated @entity1140 well. The most frequent side-effects were neuropsychological and behavioral symptoms in three @entity1 , ranging from @entity1278 with @entity353 , @entity2588 , @entity308 and school problems to severe @entity22 and to aggressive and @entity146 in one @entity1 . Only the latter @entity1 was exposed to toxic @entity1140 blood levels. All side-effects were fully reversible after discontinuation of @entity1140 . In conclusion, @entity1140 had a beneficial effect on renal function and was well tolerated in the majority of pediatric @entity1 . However, neuropsychologic and behavioral side-effects are important and maybe underrecognized in @entity1 .

Neuropsychologic side-effects of XXXX in pediatric renal transplantation.

@entity1 :: ('9606', 'Species') :: ['child', 'children', 'patients', 'girls'] @entity14855 :: ('CHEBI:53439', 'Chemical') :: ['Calcineurin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity146 :: ('MESH:D001523', 'Disease') :: ['anxious behavior'] @entity1009 :: ('966', 'Gene') :: ['min/1'] @entity1278 :: ('MESH:D000856', 'Disease') :: ['anorexia nervosa-like symptoms'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus', 'tacrolimus'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea'] @entity16757 :: ('MESH:D054038', 'Disease') :: ['posterior leukoencephalopathy syndrome'] @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']
@entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']
